X-154534125-C-T
Variant summary
Our verdict is Likely pathogenic. Variant got 6 ACMG points: 7P and 1B. PM1PM5PP3_ModeratePP5BS2_Supporting
The ENST00000393562.10(G6PD):c.680G>A(p.Arg227Gln) variant causes a missense change. The variant allele was found at a frequency of 0.0000636 in 1,210,410 control chromosomes in the GnomAD database, with no homozygous occurrence. There are 30 hemizygotes in GnomAD. In-silico tool predicts a pathogenic outcome for this variant. Variant has been reported in ClinVar as Conflicting classifications of pathogenicity (no stars). Another variant affecting the same amino acid position, but resulting in a different missense (i.e. R227L) has been classified as Pathogenic.
Frequency
Consequence
ENST00000393562.10 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Likely_pathogenic. Variant got 6 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
G6PD | NM_001360016.2 | c.680G>A | p.Arg227Gln | missense_variant | 7/13 | ENST00000393562.10 | NP_001346945.1 | |
G6PD | NM_000402.4 | c.770G>A | p.Arg257Gln | missense_variant | 7/13 | NP_000393.4 | ||
G6PD | NM_001042351.3 | c.680G>A | p.Arg227Gln | missense_variant | 7/13 | NP_001035810.1 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
G6PD | ENST00000393562.10 | c.680G>A | p.Arg227Gln | missense_variant | 7/13 | 1 | NM_001360016.2 | ENSP00000377192 | P4 |
Frequencies
GnomAD3 genomes AF: 0.0000713 AC: 8AN: 112270Hom.: 0 Cov.: 23 AF XY: 0.000174 AC XY: 6AN XY: 34432
GnomAD3 exomes AF: 0.0000491 AC: 9AN: 183199Hom.: 0 AF XY: 0.000103 AC XY: 7AN XY: 67687
GnomAD4 exome AF: 0.0000628 AC: 69AN: 1098140Hom.: 0 Cov.: 32 AF XY: 0.0000660 AC XY: 24AN XY: 363506
GnomAD4 genome AF: 0.0000713 AC: 8AN: 112270Hom.: 0 Cov.: 23 AF XY: 0.000174 AC XY: 6AN XY: 34432
ClinVar
Submissions by phenotype
Anemia, nonspherocytic hemolytic, due to G6PD deficiency Pathogenic:2Uncertain:1
Pathogenic, criteria provided, single submitter | clinical testing | Mendelics | May 04, 2022 | - - |
Pathogenic, criteria provided, single submitter | curation | Dunham Lab, University of Washington | Aug 12, 2022 | Variant found in hemizygote with deficiency (PP4). Decreased activity in red blood cells (35%) (PS3). Affects same amino acid as pathogenic 227R>L (ClinVar ID 10387) (PM5). Below expected carrier frequency in gnomAD (PM2). Reported as pathogenic by ARUP Laboratories (PP5). Post_P 0.994 (odds of pathogenicity 1517, Prior_P 0.1). - |
Uncertain significance, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Aug 23, 2022 | This sequence change replaces arginine, which is basic and polar, with glutamine, which is neutral and polar, at codon 227 of the G6PD protein (p.Arg227Gln). This variant is present in population databases (rs137852328, gnomAD 0.02%). This missense change has been observed in individual(s) with G6PD deficiency (PMID: 1611091). This variant is also known as G6PD Mexico City. ClinVar contains an entry for this variant (Variation ID: 10395). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is expected to disrupt G6PD protein function. Experimental studies have shown that this missense change affects G6PD function (PMID: 25407525). Algorithms developed to predict the effect of sequence changes on RNA splicing suggest that this variant may create or strengthen a splice site. This variant disrupts the p.Arg227 amino acid residue in G6PD. Other variant(s) that disrupt this residue have been observed in individuals with G6PD-related conditions (PMID: 10571945), which suggests that this may be a clinically significant amino acid residue. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. - |
not specified Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | ARUP Laboratories, Molecular Genetics and Genomics, ARUP Laboratories | Sep 21, 2018 | - - |
G6PD deficiency Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Illumina Laboratory Services, Illumina | Jan 12, 2018 | This variant was observed in the ICSL laboratory as part of a predisposition screen in an ostensibly healthy population. It had not been previously curated by ICSL or reported in the Human Gene Mutation Database (HGMD: prior to June 1st, 2018), and was therefore a candidate for classification through an automated scoring system. Utilizing variant allele frequency, disease prevalence and penetrance estimates, and inheritance mode, an automated score was calculated to assess if this variant is too frequent to cause the disease. Based on the score, this variant could not be ruled out of causing disease and therefore its association with disease required further investigation. A literature search was performed for the gene, cDNA change, and amino acid change (if applicable). No publications were found based on this search. This variant was therefore classified as a variant of unknown significance for this disease. - |
G6PD MEXICO CITY Other:1
other, no assertion criteria provided | literature only | OMIM | May 24, 2017 | - - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at